(Q47684766)

4 February 2018

title

Genetics: Predictive value of KRAS mutations in chemoresistant CRC. (English)

1 reference

4 February 2018

author

Pierre Laurent-Puig

series ordinal

2

1 reference

4 February 2018

author name string

Astrid Lièvre

series ordinal

1

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 June 2009

1 reference

4 February 2018

Nature Reviews Clinical Oncology

published in

1 reference

4 February 2018

volume

6

1 reference

4 February 2018

issue

6

1 reference

4 February 2018

page(s)

306-307

1 reference

4 February 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

Cetuximab for the treatment of colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.69

10.1038/NRCLINONC.2009.69

31 March 2020

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

19483733

1 reference

4 February 2018